RxDoctor Payments Data

Eli Friedman, MD

Cardiovascular Disease · Los Angeles, CANPI 1780973644

Payments from drug & device makers

$4,487in general payments, 2019–2025

Across 27 payments — averaging $166.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viz.ai, Inc.$3K
  • Medtronic$461
  • Boston Scientific$380
  • E.r. Squibb & Sons, L.L.C.$170
  • Abbott$134
  • Pfizer$86
  • plus $90 from 3 others

What the payments were for

  • Consulting fees$2,55057%
  • Food & beverage$1,93743%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,487 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$159,335
Medicare patients
1,093
Services billed
2,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban209$235,931
EntrestoSacubitril/Valsartan51$61,826
XareltoRivaroxaban45$50,561
Repatha SureclickEvolocumab27$31,855
FarxigaDapagliflozin Propanediol25$28,474
Repatha SyringeEvolocumab18$22,369
Praluent PenAlirocumab16$21,057
Icosapent Ethyl13$4,801
Metoprolol Succinate162$2,868
Rosuvastatin Calcium159$2,148
Losartan Potassium149$1,647
Atorvastatin Calcium189$1,580
Nifedipine ErNifedipine25$1,575
Bisoprolol Fumarate50$1,292
Carvedilol145$1,051

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$86$235,931209 claims
NovartisEntresto$29$61,82651 claims
Johnson & JohnsonXarelto$31$50,56145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →